Skip to main content
OpenTrials
Recruiting

NCT Number: NCT05079841

The Stimulation To Induce Mothers Study

The investigators propose a parallel group randomized clinical trial of intrapartum nipple stimulation versus exogenous oxytocin infusion for nulliparous women undergoing induction of labor near term. The central hypothesis is that intrapartum nipple stimulation to induce labor increases spontaneous vaginal delivery, improves patient-centered outcomes such as childbirth satisfaction, labor agentry, and pain scores, and reduces adverse neonatal and maternal outcomes in nulliparous women. The investigators will pursue the following specific aims: 1) Assess the effectiveness of intrapartum nipple stimulation on the rate of spontaneous vaginal delivery in nulliparous women, 2) Breastfeeding as the sole source of nutrition at time of maternal hospital discharge (Primary Aims); 3) Maximal percent newborn weight loss during the birth hospitalization within 72 hours of life, 4) Determine the effect of intrapartum nipple stimulation on the rate of adverse maternal and neonatal outcomes, 5) Determine the impact of intrapartum nipple stimulation on patient-centered outcomes and 6) In a sub-cohort of women who are enrolled in the trial, investigators will measure the change in oxytocin concentration from baseline to time at which patient achieves a regular contraction pattern.

Recruiting

Interested in participating?

Request Info

Key information

Age range

18 year and older

Sex eligibility

Female

Study type

Interventional

Phase

Phase 4

Primary location

Yale New Haven Hospital, New Haven, Connecticut, United States

Loading trial locations.

About this study

Primary Objectives

  • To determine whether intrapartum nipple stimulation therapy with or without synthetic oxytocin changes the likelihood of achieving a spontaneous vaginal delivery compared to receipt of synthetic oxytocin infusion without nipple stimulation to induce labor.
  • Breastfeeding as the sole source of nutrition at time of maternal hospital discharge

Secondary Objectives (if applicable)

The secondary objectives are as follows:

  • Determine whether intrapartum nipple stimulation therapy with or without synthetic oxytocin changes the likelihood of achieving a spontaneous vaginal delivery compared to receipt of synthetic oxytocin infusion without nipple stimulation to induce labor.
  • Determine if women who perform intrapartum nipple stimulation to induce labor have differences in other obstetric and maternal outcomes
  • Determine if women who perform intrapartum nipple stimulation report differences in pain scores during labor, labor agentry and satisfaction scores, postpartum depression scores, and breastfeeding success compared to women who receive only intrapartum exogenous oxytocin infusion.
  • Determine if women who perform intrapartum nipple stimulation to induce labor have similar fetal and neonatal outcomes compared to women who receive only intrapartum exogenous oxytocin infusion.
  • Maximal percent newborn weight loss during the birth hospitalization within 72 hours of life
  • At Yale, to measure the change in oxytocin concentration from baseline over the course of labor induction in patients undergoing induction of labor via intrapartum nipple stimulation versus continuous exogenous oxytocin infusion.
  • At Yale, to measure circulating plasma and urine concentrations of proteins, microRNA, and small molecules using unbiased "omics" approaches, comparing patients undergoing induction of labor via intrapartum nipple stimulation versus continuous exogenous oxytocin infusion, un-ripened/unlabored control patients, and patients in spontaneous labor.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Nulliparous
  • Gestational age 36 0/7 weeks and greater at enrollment
  • Singleton gestation
  • Planned to undergo initiation of exogenous oxytocin infusion by their maternity care provider
  • Spontaneous rupture of membranes or if membranes intact, modified Bishop score ≥5 and cervix dilated <6 cm within one hour of enrollment
  • Ability to give informed consent

Exclusion criteria

  • Unable to understand English or Spanish
  • Prior use of exogenous oxytocin or attempt at nipple stimulation during the current pregnancy
  • Presence of tachysystole (defined as more than 5 contractions in 10 minutes averaged over 30 minutes), recurrent variable or late fetal decelerations, and bradycardia in the prior 30 minutes before enrollment
  • Non-vertex presenting fetus at time of enrollment
  • Planned for cesarean delivery or contraindication to labor by institutional policy (e.g., placenta previa, vasa previa, active genital herpes infection, previous transmural myomectomy)
  • Multi-fetal gestation (e.g., twins, triplets, and higher-order multiples)
  • Intrauterine fetal death
  • Major fetal anomaly suspected prenatally (defined as a fetal anomaly with anticipated neonatal intensive care unit admission)
  • Suspected alloimmunization (given the increased likelihood for anticipated neonatal intensive care unit admission)
  • Known severe fetal growth restriction (estimated fetal weight <3rd percentile) or abnormal umbilical artery Doppler studies (given the increased likelihood for anticipated neonatal intensive care unit admission)
  • HIV infection (nipple stimulation is not encouraged given the recommendation for these mothers not to breastfeed)
  • Participation in another interventional study that influences management of labor and delivery or perinatal morbidity or mortality
  • History of mastectomy or other contraindication to use of electronic breast pump
  • Known allergic reactions to components of the electronic breast pump or to synthetic oxytocin intravenous solution
  • Significantly impaired consciousness or executive function (e.g., intubated or sedated)

Treatment and study plan

Electric breast pump

Device

Participants randomized to the intrapartum nipple stimulation will use electric breast pump or nipple stimulate by hand (if preferred) (intervention) to induce labor for at least 2 hours

Exogenous oxytocin intravenous infusion without nipple stimulation.

Drug

Participants randomized to the standard care arm will use exogenous oxytocin intravenous infusion to induce labor as current standard of care

Other names: Pitocin intravenous infusion

Primary outcomes

  1. Spontaneous vaginal delivery

    Time frame: At delivery

    Spontaneous vaginal delivery will be defined as delivery that occurs without the use of forceps, vacuum, or cesarean

  2. Breastfeeding as the sole source of nutrition (BSSN)

    Time frame: up to 72 hours following delivery

    Number of participants using breastfeeding as the sole source of nutrition (BSSN) at time of maternal discharge or 72 hours of life (whichever is sooner)

Secondary outcomes

  1. Operative vaginal delivery

    Time frame: At delivery

    Delivery with the assistance of forceps or vacuum, and indication

  2. Cesarean delivery

    Time frame: At delivery

    Delivery by cesarean section

  3. Labor induction duration

    Time frame: At delivery

    Time interval from randomization to delivery

  4. Number of Participants with Postpartum hemorrhage

    Time frame: From delivery to 24 hours postpartum

    Cumulative blood loss of ≥1,000 mL within 24 hours after the birth process

  5. Number of Participants with Severe Postpartum hemorrhage

    Time frame: From delivery to 24 hours postpartum

    Transfusion; non-elective hysterectomy; use of ≥2 uterotonic medications other than oxytocin; other interventions such as uterine compression sutures, uterine artery ligation or embolization, hypogastric artery ligation, balloon tamponade

  6. Number of participants with suspected infection

    Time frame: 3-7 days postpartum

    Suspected intraamniotic infection, intrapartum chorioamnionitis, or postpartum endometritis (defined as maternal fever ≥38° Fahrenheit with planned or initiated administration of therapeutic antibiotics) after randomization and prior to delivery hospitalization discharge

  7. Lactational mastitis

    Time frame: After delivery to 12 weeks postpartum

    Subject-reported occurrence of lactational mastitis

  8. Number of maternal deaths

    Time frame: immediately prior to up to immediately post delivery

    Incidence of maternal death prior to, during, or post delivery

  9. Maternal Intensive Care Unit admission

    Time frame: 3-7 days postpartum

    Any admission to the Intensive Care Unit after delivery and prior to delivery hospitalization discharge

  10. Neonatal Intensive Care Unit admission

    Time frame: up to 28 days following birth

    Any admission to the Neonatal Intensive Care Unit From birth to birth hospitalization discharge or 28 days after birth, whichever is earlier

  11. Neonatal Apgar score ≤3 at 5 minutes of life

    Time frame: At 5 minutes after birth

    The Neonatal Apgar score is scored from 0 to 10. A 5-minute Apgar score of 0-3 correlates with neonatal mortality in large population studies.

  12. Umbilical acidemia

    Time frame: At delivery

    Umbilical cord arterial pH <7.0 or base excess >12 mmol/L; or umbilical cord venous pH <7.0 or base excess >12 mmol/L if arterial blood sample not available

  13. Composite neonatal severe morbidity measure

    Time frame: up to 28 days following delivery

    Intrapartum fetal death or neonatal death; cardiorespiratory support within first 72 hours of life; neonatal encephalopathy; seizures; hypothermic treatment (cooling); sepsis; pneumonia; major birth injury; meconium aspiration syndrome; intracranial hemorrhage or subgaleal hemorrhage; or hypotension requiring pressor support

  14. Percent newborn weight loss

    Time frame: At 72 hours of life or birth hospitalization discharge, whichever is earlier

    Maximal percent newborn weight loss in kilograms(kg)

Other outcomes

  1. Subject-reported pain during childbirth

    Time frame: At intervention start and than again 2 hours after intervention start

    Visual analog scale, scored with Likert scale from 0 (no pain) to 10 (worst pain)

  2. Subject-reported satisfaction during labor and childbirth

    Time frame: 6-96 hours after delivery

    Birth Satisfaction Scale-Revised (BSS-R) is a 10-item self-report valid and reliable measure (scores range from 0 to 40, 0 being the least satisfaction and 40 being the most satisfaction)

  3. Subject-reported feelings of control during labor and childbirth

    Time frame: 6-96 hours after delivery

    Labor Agentry Scale is a 29-item survey designed to assess expectations and experiences of personal control during childbirth (scores range from 29 to 203, with higher scores indicating greater perceived control during childbirth)

  4. Subject-reported depression score

    Time frame: 4 to 12 weeks after delivery

    Edinburgh Postnatal Depression Scale is a 10-item self report scored from 0 to 30; score >10 warrants additional clinical assessment for depression

  5. Subject-reported breastfeeding success

    Time frame: 4 to 12 weeks after delivery

    Maternal Breastfeeding Evaluation Scale (MBES) is a 30-item using a 5-point Likert scale with higher scores reflecting more positive breastfeeding experiences.

  6. Subject-reported ability to express and/or collect colostrum and/or breastmilk intrapartum

    Time frame: From randomization to hospital discharge, approximately 3-7 days

    Participants ability to express and/or collect colostrum and/or breastmilk intrapartum

  7. Subject-reported perception of milk supply

    Time frame: 2 weeks postpartum

    Subject-reported perception of milk supply using the validated Perception of Insufficient Milk Supply (PIMS). PIM is defined as a state in which a mother has or perceives that she has an inadequate supply of breast milk to meet her infant's needs. A perception of insufficient milk supply is associated with early discontinuation of breastfeeding.

Study contacts

Contact information is provided by the study sponsor or research team.

Moeun Son, MD, MSCI

CONTACT

[email protected]

(212) 746-2106

Molly McAdow, MD, PhD

CONTACT

[email protected]

Sponsors and collaborators

Lead sponsor

Yale University

Other

Collaborators

  • Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)

Registry information

Official study title

The Stimulation To Induce Mothers (STIM) Study: A Parallel Group Randomized Controlled Trial

Acronym: STIM

Important dates

Study start
2021
Primary completion
2028
Study completion
2029
First posted
Oct 15, 2021
Registry last updated
Mar 24, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.